Application of hybridAPC in the Treatment of Barrett

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-12-05

Study Completion Date

2021-12-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the efficacy and safety of the new technique of HybridAPC in the treatment of Barrett.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy of CryoBalloon Focal Ablation System on Human Esophageal Barrett's Epithelium

NCT02249975

Barrett's Esophagus

COMPLETED NA

EndoRotor® Ablation of Barrett's Esophagus: Safety and Feasibility Study

NCT03120195

Barretts Esophagus With Dysplasia

COMPLETED NA

Evaluation of Effect of CryoBalloon Focal Ablation System on Human Esophageal Barrett's Epithelium

NCT01633411

Barrett's Esophagus

COMPLETED

Non-Endoscopic Surveillance for Barrett's Esophagus Following Ablative Therapy

NCT02106910

Barrett's Esophagus

COMPLETED NA

Multi-center Clinical Study to Evaluate the C2 CryoBalloon Focal Ablation System

NCT02514525

Barrett Esophagus

ACTIVE_NOT_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

After thermal ablation of Barrett's esophagus, stricture formation is reported in 5 to over 10% of patients. Submucosal fluid injection prior to ablation may lower the risk of stricture formation. The new technique of HybridAPC which combines submucosal injection with APC is considered to reduce the complication.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Barrett's Esophagus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HybridAPC

The patient with Barrett's esophagus is treatment by HybridAPC.

Group Type EXPERIMENTAL

HybridAPC

Intervention Type DEVICE

HybridAPC is a device which combines submucosal fluid injection with APC

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HybridAPC

HybridAPC is a device which combines submucosal fluid injection with APC

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients age is from 18 to 70.
2. Patients who were diagnosed with Barrett's esophagus.
3. Informed consent.

Exclusion Criteria

1. Patient with severe cardiopulmonary dysfunction is unable to tolerated by endoscopy.
2. Severe bleeding tendency.
3. Poor compliance.
4. Patient is very ill and life expectancy is less than 2 years.
5. Esophageal varices or venous aneurysms, and no effective prevention or treatment for bleeding.
6. Severe esophageal stenosis.
7. Pregnancy.
8. Lesion is located in esophageal diverticulum or spread their diverticulum.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No